About this trial
The study aims to assess whether it is feasible to routinely test all women with a newly diagnosed or a recurrent ovarian cancer for a mutation in the BRCA1 and BRCA2 genes when they present to the oncology clinic, using both tumour and blood samples.
We want to find out whether patients and their cancer team are satisfied with this new approach. We also want to look at the financial costs and clinical benefits of performing BRCA1 and BRCA2 mutation testing in this way. In addition, we want to collect information on the treatment and behaviour of ovarian cancers with a BRCA1 or BRCA2 mutation, as compared to ovarian cancers that do not have these mutations.
Patients diagnosed with high grade serous or endometrioid ovarian, fallopian tube or primary peritoneal cancer are eligible for this study. For this study patients will be requested for permission to access their ovarian cancer tissue samples which were taken in a previous biopsy or surgery and to donate a blood sample. These will be sent for BRCA1/BRCA2 mutation testing.The result of these tests will be explained to the patient by the doctor within 12 weeks. Patients will also be requested to complete a questionnaire regarding satisfaction with the testing and results process, after the test result has been explained to them. Permission to access medical records and to collect specific data relating to the cancer diagnosis, cancer treatment and outcomes will also be requested for this research study.
Where’s this trial being run?Bon Secours Cork, Cork University Hospital, St James’s Hospital, University Hospital Limerick, University Hospital Waterford, Mater Misericordiae University Hospital, and Mater Private Hospital
Can I join this study / trial?
The first thing you do is to talk to your doctor and/or the cancer trials research team in your hospital. The contact details for the cancer trials research units in Ireland is here.
Why not Print this page and bring it with you. It will help your doctor and research team advise you.Print this page
For more detailed informationClick Here
|Name:||The tBRCA Study|
Upfront systematic tumour BRCA testing in patients with high grade serous or endometrioid ovarian, fallopian tube or primary peritoneal cancer: The t-BRCA Study
|Principal Investigator:||Chief Investigator Prof Bryan Hennessy (Beaumont Hospital), Co-Investigator Dr Roshni Kalachand (RCSI)|
Cancer Trials Ireland
Ireland: Q1 2019
|Global Recruitment Target:||N/A|
|Ireland Recruitment Target:||200|